Long-term responders

Long-term treatment: LUX-Lung 3, 6, 7 and 8

In the LUX-Lung 3, LUX-Lung 6 and LUX-Lung 7 studies, 10–12% of afatinib-treated* patients were long-term responders (LTRs; treated for ≥3 years).1 In LUX-Lung 7, 12% of afatinib-treated patients versus 4% of gefitinib patients were LTRs. Long-term treatment was independent of tolerability-guided dose adjustment and of the presence of brain metastases at time of enrolment. Long-term treatment with afatinib had no detrimental impact on subsequent treatment.1

Patients treated for at least 2, 2.5 and 3 years in the overall LUX-Lung 3, 6 and 7 populations1,2

Long-term treatment in LUX-Lung 3, LUX-Lung 6 and LUX-Lung 7

Note: For LUX-Lung 7, percentages are based on total number of patients who received treatment with afatinib or gefitinib

LL; Lux-Lung.

In LUX-Lung 8, 21 out of 398 patients in the afatinib arm were long-term responders who had received at least 12 months of afatinib treatment.3 Median treatment duration in these patients was 17.6 months (range 12.3–27.6 months). Median progression-free survival (PFS) was 16.6 months (range 2.8–25.8) and median overall survival (OS) was 21.1 months (range 12.9–31.6); one patient had a complete response and six patients had a partial response.3

Did you find this information useful?



Schuler M, et al. Eur J Cancer 2017;72(Suppl. 1):S176-S7.


Yang JC-H, et al. Presented at the 2017 Japanese Society of Medical Oncology Annual Meeting (Abstract 70046).


Gadgeel SM, et al. Eur J Cancer 2017;72(Suppl. 1):S185.

*Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.


© 2018 Boehringer Ingelheim International GmbH. All rights reserved.

Last updated: October 2018